CLINI CAL TRIALS

We share our experience, helping to avoid costly beginner`s mistakes when launching a new product or line of business.

BCD-066-2
STATUS: SETTING

A Multicenter, Double-blind, Randomized, Parallel, Comparative Study of Efficacy and Safety of BCD-066 (CJSC BIOCAD, Russia) and Aranesp® (Amgen Europe B.V., Netherlands) in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis.

BCD-109-1
STATUS: COMING SOON

A multicenter, open-label, randomized clinical study of the efficacy and safety of BCD-109 (CJSC BIOCAD, Russia) versus Venofer® (Vifor (International) Inc., Switzerland) in the therapy of iron deficiency anemia in chronic kidney disease patients who do not need dialysis. Eligible population included both male and female patients aged from 18 to 75 years old (inclusive) with diagnosed iron deficiency anemia or anemia of combined genesis (iron deficiency + anemia of chronic disease) that developed due to chronic kidney disease, who do not need dialysis and receive erythropoiesis-stimulating therapy.